Lindsay Rosenwald initiated his professional studies at Pennsylvania State University in 1973 after graduating from Abington High School. He excelled a business and was particularly fascinated with economics and finance. He was a member of Beta Gamma Sigma, the business school’s honors society. In 1977, he graduated with his Bachelors degree in Finance. Despite his aptitude and curiosity about business, Lindsay Rosenwald had always aspired to become a doctor.

His initial step in completing his dream was to get accepted to a medical school, which he did, and started to attend Temple University. After finishing his studies at Temple, he was accepted into an internship at Abington medical center. He worked as a medical doctor in his practice for 2 . 5 years. Although he liked practicing medicine Dr. Lindsay Rosenwald felt as if something was lacking. He made the decision he needed to incorporate his 2 pursuits, business and medicine, and locate a career that would let him peruse those passions.

Rosenwald left his private practice in 1986 to head to Wall Street where he took on a position as a Physician / Analyst, a really exclusive position with only a few people doing it at that time. Despite the stereotype that doctors don’t make good investors, Dr Rosenwald excelled at this placement. He had an eagerness for growing investment capital available to the health care sector and that’s mainly why he worked there. He received great respect in his brand new position, and even though he missed his old private practice, he recognized this is where he actually belonged. He also worked for an exclusive investment firm, DH Blair Co as the Managing Director of Finance, but left after a few years to concentrate on a new venture.

Rosenwald , president of Paramount Biotech, made it profitable by acquiring other biotech organizations and making them a part of his portfolio. The business has financed more than two dozen companies within the last three years. He creates these firms by focusing on the growth of both the corporate and biotechnology portions. Paramount Capital is a conglomerate of firms including: Paramount biosciences, Paramount Corporate Development and Paramount BioCapital. All of these companies are separate entities, but work together to support one another. The businesses that Lindsay Rosenwald handles have licensed or acquired over one hundred experimental stage treatments.

Perhaps one of Dr Rosenwald’s finest accomplishments is that he set the record for the quickest development of a drug. In a little over 2 years, Arsenic Trioxide was researched, tested, approved and delivered to market for managing the leukemia disease. It can be credited with saving thousands of lives in the decade it has been on the market.

Rosenwald has been revolutionary with the businesses he has created. In one of the very best reverse takeovers of them all, his firm, Cougar Biotechnology, sold for over $1 billion to Johnson and Johnson, in spite of only having an individual drug with phase two clinical data. He is also the reason for bringing a stem cell business, a cancer vaccine business, and a gene treatment company all to market. As Lindsay Rosenwald as the director, his companies have created many of the most valuable and groundbreaking drugs of the 21st century. To add to his accomplishments he came up with the very first successful medicine to help those who are obese.

One of the reasons that Rosenwald’s companies have been prosperous is that he hires PhDs, MDs, MBAs, and other specialists to function as his senior level professionals. These people often have qualification in business, but they additionally tend to have vast knowledge in the healthcare community. They attempt to produce new medications with great focus and efficiency. These companies are blazing the trail of new medicines and treatment options that will change the concept of medicine.

Lindsay Rosenwald has built his business by regularly looking towards the future and now is no exclusion. Dr Rosenwald believes that there will probably continue to be rapid growth within the biotechnology sector within the subsequent twenty years. At the rate it is developing, this growth will be exponential. According to Rosenwald, upcoming medical breakthroughs will come via small biotech companies that are concentrated in on generating just a few products, as opposed to a giant biotech company that has many tasks in work at once. Rosenwald believes that emphasis ought to now be placed on discovering remedies for 2 of society’s greatest healthcare dangers – heart disease and cancer.

Related posts:

  1. Lindsay Rosenwald’s Impact
  2. Biotechnology Company | Paramount
  3. The Unique Structure of the Paramount Group
  4. Yoshuv Institute – Rosenwalds